Clinical trials: Lymphomas Non-Hodgkin's B-Cell
Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
The purpose of this study is to determine safety, tolerability, dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory lymphoproliferative malignancies (LPM) or…
- Trial name
- NCT02238522
- Testing
- ZEN003365
- Where
- 4 sites in United States
- Sponsor
- Zenith Epigenetics
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Patients eligible for the study will receive R-DA-EDOCH as the induction therapy and be evaluated by PET CT after the fourth cycle.
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma
- Trial name
- NCT03837873
- Testing
- Rituximab, Etoposide, Vincristine
- Where
- 6 sites in China
- Volunteers
- 118 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or…
- Trial name
- NCT04442022
- Testing
- Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy)
- Where
- 38 sites in United States, China and 4 more
- Volunteers
- 501 people
- Sponsor
- Karyopharm Therapeutics Inc
Lymphoma, Small Intestine Cancer
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced solid…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004002
- Testing
- bortezomib
- Where
- 5 sites in United States
- Sponsor
- NYU Langone Health
Lymphoma
Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00039351
- Testing
- cyclophosphamide, prednisone, vincristine sulfate
- Where
- 17 sites in Belgium, Egypt and 5 more
- Volunteers
- 32 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-Hodgkins Lymphoma
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for…
- Trial name
- NCT01281917
- Testing
- Velcade, Temsirolimus
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Wisconsin, Madison
Non-Hodgkin's Lymphoma
Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
Primary Objective: To determine the toxicity profile and maximum tolerated dose (MTD) of VELCADE when administered in combination with CHOP + Rituximab to patients with previously untreated diffuse large B cell or mantle cell…
- Trial name
- NCT00151320
- Testing
- Bortezomib, CHOP, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 76 people
- Sponsor
- Weill Medical College of Cornell University
Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Primary Objective: To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for SAR245409 when administered in combination with rituximab or bendamustine plus rituximab Secondary Objectives: To determine…
- Conditions
- Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01410513
- Testing
- SAR245409
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Sanofi
B-cell Non-Hodgkin Lymphoma
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
The aim of this study was to analyze the safety and efficacy of CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells for the treatment of relapsed and refractory B-cell Non-Hodgkin's （B-NHL） lymphoma.
- Trial name
- NCT06464185
- Testing
- Bispecific antibody-based combined with CAR-T cell therapy
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia, Lymphoma
Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
This study aims to evaluate the safety, efficacy and duration of response of anti-CD19 anti-CD20 Bispecific Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ and CD20+…
- Trial name
- NCT03271515
- Testing
- anti-CD19 anti-CD20 Bispecific CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Doing Biomedical Co., Ltd.
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed/Refractory B-cell Lymphoma
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
This single-arm, open-label pilot study will assess the safety and efficacy of RN1701, a bispecific CD19/CD20-targeted allogeneic CAR-T-cell product, in patients with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT07563543
- Testing
- RN1701 injection
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Large B-cell Lymphoma
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
This is a phase ll study of participants with large B Cell lymphoma previously treated with anti-CD19 Chimeric antigen receptor (CAR-T) therapy.
- Trial name
- ZeTA (NCT06167785)
- Testing
- Tislelizumab, Zanubrutinib, Tislelizumab + Zanubrutinib
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Adult Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Recurrent
A Phase II Study of Doxycycline in Relapsed NHL
The purpose of this study is to determine whether doxycycline is effective in the treatment of relapsed Non Hodgkin Lymphomas (NHL).
- Conditions
- Adult Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Recurrent, Lymphoma, Follicular, Marginal Zone B-Cell Lymphoma
- Trial name
- NCT02086591
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Rochester
Lymphoma
Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01131208
- Testing
- gene expression analysis, laboratory biomarker analysis
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
- Trial name
- VITALIZE (NCT04920617)
- Testing
- DPX-Survivac, Pembrolizumab, CPA
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Lymphoma, Large B-Cell, Diffuse
Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)
This study will evaluate IgNGS at different time points in newly diagnosed DLBCL patients homogeneously treated (RCHOP) to address its correlation with conventional techniques (i.e., positron emission tomography/computed…
- Trial name
- NCT04237168
- Testing
- IgNGS from circulating tumor DNA
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Follicular Lymphoma, Diffuse Large B Cell Lymphoma
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy…
- Conditions
- Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05255354
- Testing
- ClonoSEQ
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Adaptive Biotechnologies
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia
The purpose of this study is to find answers to the following questions: What is the largest dose of AQ4N that can be given safely one time every three weeks for 24 weeks? What are the side effects of AQ4N when given according to…
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT00109356
- Testing
- AQ4N (Chemotherapy)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Novacea